^
Association details:
| Biomarker: | ER positive + ZNF217 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | dimethyl fumarate (CU01) (TGFβ inhibitor, NRF2 activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers
Published date:
07/21/2023
Excerpt:
MF's in vivo activity was evaluated in a xenograft model of MCF-7 HER2 cells that have elevated expression of ZNF217 and DMF treatment resulted in significant inhibition of tumor growth….These data indicate that DMF's anti-breast cancer activities in the ER+HER2+models, at least in part, are due to inhibition of ZNF217.
DOI:
https://doi.org/10.1007/s10549-023-07037-4
